Clinical Trials
22 trialsNCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT02158507 2026-01-22
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
University of Alabama at Birmingham
Phase NA Completed
NCT01489865 2025-11-06
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
Georgetown University
Phase 1/2 Completed
NCT01818063 2025-04-30
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
Phase 2 Completed
NCT01009788 2025-03-14
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT01205828 2025-02-12
ABT-888 and Temozolomide for Liver Cancer
Georgetown University
Phase 2 Terminated
NCT03061188 2024-06-12
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma
Northwestern University
Phase 1 Completed
NCT01618357 2024-05-22
Pre-Operative Radiation and Veliparib for Breast Cancer
Indiana University
Phase 1 Completed
NCT03044795 2024-05-03
REPAIR
University Medical Center Groningen
Phase 2 Withdrawn
NCT04774406 2023-06-06
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
University Hospital, Caen
Completed
NCT04774627 2021-09-23
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
University Hospital, Caen
Completed
NCT02985658 2021-07-21
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
University of Washington
No longer available
NCT03227016 2021-01-27
Study in Patients With SCLC of Veliparib in Combination With Topotecan
Central European Society for Anticancer Drug Research
Phase 1 Unknown
NCT01908478 2020-07-15
VelGemRad
Cedars-Sinai Medical Center
Phase 1 Completed
NCT01051596 2019-04-02
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
Georgetown University
Phase 2 Completed
NCT00770471 2018-06-27
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT01477489 2017-12-15
Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT03032614 2017-10-10
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn
NCT02831179 2017-09-28
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT01104259 2017-08-10
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
University of Washington
Phase 1 Completed
NCT01472783 2016-11-16
Veli-BRCA
Vejle Hospital
Phase 1/2 Completed
NCT01690598 2015-06-10
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
Vejle Hospital
Phase 1/2 Completed